Results 111 to 120 of about 389,774 (312)

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska   +2 more
wiley   +1 more source

Characterizing chest pain in patients with acute coronary syndrome at Vietnam National Heart Institute: a case-control study

open access: yesJournal of International Medical Research
Objective This study aimed to distinguish chest pain characteristics between patients with and without acute coronary syndrome (ACS) at Vietnam National Heart Institute.
Lan Anh Nguyen   +5 more
doaj   +1 more source

Oesophageal chest pain [PDF]

open access: yesGut, 1984
H A, Davies   +3 more
openaire   +2 more sources

Extremity Function After Transfemoral Transcatheter Aortic Valve Implantation: A TAVI XS Sub‐Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Physical decline after transcatheter aortic valve implantation (TAVI) is associated with worse outcomes. However, data on post‐TAVI extremity function are limited. This sub‐study of the TAVI XS trial aimed to assess extremity function after transfemoral TAVI, evaluate functional decline, compare outcomes between upper‐and lower ...
Geert A. A. Versteeg   +20 more
wiley   +1 more source

Prevalence and outcome of patients referred for chest pain with high‐sensitivity troponin elevation and no diagnosis at discharge [PDF]

open access: bronze, 2018
Vincent Lordet   +6 more
openalex   +1 more source

Chest pain observation unit: A missed opportunity to initiate smoking cessation therapy [PDF]

open access: green, 2023
Nicklaus P. Ashburn   +9 more
openalex   +1 more source

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617)
Jenny‐Hoa Nguyen   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy